APAC IPOs & Placements, Aequitas Research

Clarence Chu

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Xiamen Yan Palace Bioengineering / Equity Capital Markets

Xiamen Yan Palace Bioengineering (1951686D CH)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/xiamen-yan-palace-bioengineering" target="_blank" data-smartkarma-citation="entities:39867:1" rel="noopener">Xiamen Yan Palace Bioengineering (1951686D CH)</a> is looking to raise around US$200m in its upcoming Hong Kong IPO. The deal will be run by CICC and GF Securities.</li>
<li>Xiamen Yan Palace Bioengineering focuses on the development, production and marketing of high-quality modern edible bird’s nest (EBN) products.</li>
<li>According to Frost &amp; Sullivan (F&amp;S), the firm is the largest EBN product company globally in terms of retail value between 2020-2022, with a market share of 4.1%.</li>
</ul>



Xiamen Yan Palace Bioengineering (1951686D CH) is looking to raise around US$200m in its upcoming Hong Kong IPO. The deal will be run by CICC and GF Securities.
Xiamen Yan Palace Bioengineering focuses on the development, production and marketing of high-quality modern edible bird’s nest (EBN) products.
According to Frost &amp; Sullivan (F&amp;S), the firm is the largest EBN product company globally in terms of retail value between 2020-2022, with a market share of 4.1%.


Xiamen Yan Palace Bioengineering (XIAMEN HK)

Xiamen Yan Palace Bioengineering Pre-IPO Tearsheet